Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma
Malignant Nasopharyngeal Neoplasm
In a phase‑3 randomized trial, induction chemotherapy with gemcitabine (1 g/m² days 1 and 8) plus cisplatin (80 mg/m² day 1, every 3 weeks) plus concurrent chemoradiotherapy improved 3‑year recurrence‑free survival (85.3 % vs 76.5 %) and overall survival (94.6 % vs 90.3 %) compared with concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
These findings support the use of gemcitabine‑based induction chemotherapy as standard care for locoregionally advanced nasopharyngeal carcinoma, potentially improving survival outcomes.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma